Literature DB >> 21630057

TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.

A Fariña-Sarasqueta1, M J E M Gosens, E Moerland, I van Lijnschoten, V E P P Lemmens, G D Slooter, H J T Rutten, Adriaan J C van den Brule.   

Abstract

AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy. PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected. The variable number of tandem repeats (VNTR) and the single nucleotide polymorphism (SNP) in the 5'untranslated region of the TS gene were genotyped.
RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p = 0.05). In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found. However, there was an association between both polymorphisms and age. Among patients younger than 60 years, the patients homozygous for 2R seemed to have a better overall survival, whereas among the patients older than 67 this longer survival was seen by the carriers of other genotypes.
CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma. However, age appears to modify the effects of TS polymorphisms on survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630057     DOI: 10.1007/s13402-011-0030-z

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  53 in total

1.  p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.

Authors:  H J Lenz; K D Danenberg; C G Leichman; B Florentine; P G Johnston; S Groshen; L Zhou; Y P Xiong; P V Danenberg; L P Leichman
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

2.  Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.

Authors:  J L Westra; H Hollema; M Schaapveld; I Platteel; K A Oien; W N Keith; R Mauritz; G J Peters; C H C M Buys; R M W Hofstra; J Th M Plukker
Journal:  Ann Oncol       Date:  2005-07-12       Impact factor: 32.976

3.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Authors:  Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz
Journal:  J Clin Oncol       Date:  2001-12-01       Impact factor: 44.544

4.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.

Authors:  Anders Jakobsen; Jens Nederby Nielsen; Niels Gyldenkerne; Jan Lindeberg
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

5.  Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer.

Authors:  Marleen J Gosens; Elna Moerland; Valery P Lemmens; Harm T Rutten; Ivonne Tan-Go; Adriaan J van den Brule
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

6.  Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.

Authors:  Thierry Lecomte; Jean-Marc Ferraz; Franck Zinzindohoué; Marie-Anne Loriot; David-Alexandre Tregouet; Bruno Landi; Anne Berger; Paul-Henri Cugnenc; Raymond Jian; Philippe Beaune; Pierre Laurent-Puig
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

7.  Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.

Authors:  Yoko Yanagisawa; Fukuto Maruta; Nobuyoshi Iinuma; Satoshi Ishizone; Naohiko Koide; Jun Nakayama; Shinichi Miyagawa
Journal:  Scand J Gastroenterol       Date:  2007-04       Impact factor: 2.423

8.  A population-based study of age-related variation in clinicopathological features, molecular. Markers and outcome from colorectal cancer.

Authors:  Melinda Morris; Cameron Platell; Barry Iacopetta
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

9.  Molecular predictors of lymph node metastasis in colon cancer: increased risk with decreased thymidylate synthase expression.

Authors:  Avo Artinyan; Rahila Essani; Jeffrey Lake; Andreas M Kaiser; Peter Vukasin; Peter Danenberg; Kathleen Danenberg; Robert Haile; Robert W Beart
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

10.  A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.

Authors:  B Iacopetta; F Grieu; D Joseph; H Elsaleh
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more
  2 in total

1.  Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.

Authors:  Wen-Juan Li; Hua Jiang; Xin-Jian Fang; Hong-Ling Ye; Ming-Huan Liu; Yan-Wen Liu; Qian Chen; Li Zhang; Jin-Yu Zhang; Chun-Luan Yuan; Qiu-Yun Zhang
Journal:  Oncol Lett       Date:  2013-02-04       Impact factor: 2.967

2.  MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells.

Authors:  Keisuke Gotanda; Takeshi Hirota; Nozomi Matsumoto; Ichiro Ieiri
Journal:  BMC Cancer       Date:  2013-08-02       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.